Helena M. A. Feenstra

Helena M. A. Feenstra

Auto-generated profile, based on publicly available information

Helena M. A. Feenstra

Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Progress in Retinal and Eye Research
Verified
Journal Article
Open access
HFHelena M.A. Feenstra
Helena M.A. Feenstra
EDElon H.C. van Dijk
Elon H.C. van Dijk
CCChui Ming Gemmy Cheung
Chui Ming Gemmy Cheung
KOKyoko Ohno-Matsui
Kyoko Ohno-Matsui
TLTimothy Y.Y. Lai
Timothy Y.Y. Lai
CBCamiel Boon
Camiel Boon
Central serous chorioretinopathy (CSC) is a relatively common disease that causes vision loss due to macular subretinal fluid leakage and it is often associated with reduced vision-related quality of life. In CSC, the leakage of subretinal fluid through defects in the retinal pigment epithelial layer's outer blood-retina barrier appears to occur secondary to choroidal abnormalities and dysfunction. The treatment of CSC is currently the subject of controversy, although recent data obtained from several large randomized controlled trials provide a wealth of new information that can be used to establish a treatment algorithm. Here, we provide a comprehensive overview of our current understanding regarding the pathogenesis of CSC, current therapeutic strategies, and an evidence-based treatment guideline for CSC. In acute CSC, treatment can often be deferred for up to 3-4 months after diagnosis; however, early treatment with either half-dose or half-fluence photodynamic therapy (PDT) with the photosensitive dye verteporfin may be beneficial in selected cases. In chronic CSC, half-dose or half-fluence PDT, which targets the abnormal choroid, should be considered the preferred treatment. If PDT is unavailable, chronic CSC with focal, non-central leakage on angiography may be treated using conventional laser photocoagulation. CSC with concurrent macular neovascularization should be treated with half-dose/half-fluence PDT and/or intravitreal injections of an anti-vascular endothelial growth factor compound. Given the current shortage of verteporfin and the paucity of evidence supporting the efficacy of other treatment options, future studies-ideally, well-designed randomized controlled trials-are needed in order to evaluate new treatment options for CSC.

1 January 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
TRThomas J. van Rijssen
Thomas J. van Rijssen
EDElon H.C. van Dijk
Elon H.C. van Dijk
RTRoula Tsonaka
Roula Tsonaka
HFHelena M.A. Feenstra
Helena M.A. Feenstra
GDGreet Dijkman
Greet Dijkman
CBCamiel Boon
Camiel Boon

30 September 2022 in Acta Ophthalmologica
Verified
Journal Article
Open access
EDElon H.C. van Dijk
Elon H.C. van Dijk
HFHelena M. A. Feenstra
Helena M. A. Feenstra
JBJakob Bjerager
Jakob Bjerager
JGJakob Grauslund
Jakob Grauslund
CBCamiel Boon
Camiel Boon
Yousif SubhiYousif Subhi
Yousif Subhi
Treatment of chronic central serous chorioretinopathy (cCSC) remains a topic of controversy. As cCSC is a disease that can wax and wane, treatment efficacy is difficult to assess especially when trials compare active treatments without any placebo/control group. In this study, we systematically reviewed short‐term efficacies of any cCSC treatment tested in randomized controlled trials (RCT) and employed network meta‐analyses to compare to non‐treatment controls. We searched 11 literature databases on 20 March 2022 for RCTs of treatment of cCSC. We identified 17 RCTs including a total of 1172 eyes. Treatments included conventional laser (44 eyes), half‐dose or half‐fluence photodynamic therapy (PDT) (298 eyes), ranibizumab (16 eyes), antioxidants (50 eyes), mineralocorticoid receptor antagonists (187 eyes), rifampicin (91 eyes), selective retina therapy (SRT) (67 eyes) and subthreshold micropulse laser (192 eyes). Compared with controls, significant benefit on complete subretinal fluid resolution was only obtained from half‐dose or half‐fluence PDT (OR: 20.6; 95% CI: 6.3–66.7; p < 0.0001) and conventional laser (OR: 36.4; 95% CI: 2.0–655.7; p = 0.015), and at an order of magnitude lower degree from SRT (OR: 3.4; 95% CI: 1.7–6.8; p = 0.00075). Compared with controls and after sensitivity analyses, significant benefit in the change in best‐corrected visual acuity was only obtained by half‐dose/‐fluence PDT (−0.13 logMAR; 95% CI: −0.20 to −0.06 logMAR; p = 0.00021). In conclusion, three treatment options provide significant improvement over no treatment: half‐dose/‐fluence PDT, conventional laser and to a much lesser degree SRT. Considering that conventional laser can only be applied for extrafoveal leaks, and the long‐term data available for PDT‐based treatments finding persisting treatment results, half‐dose or half‐fluence PDT is the only viable treatment option for patients with cCSC. Shortage issues with verteporfin should not lead to employment of ineffective treatment modalities, as they put patients at unnecessary risk of adverse events.

11 February 2026 in Acta Ophthalmologica
Verified
Journal Article
Open access
HFHelena M. A. Feenstra
Helena M. A. Feenstra
IMIssam El Mansori
Issam El Mansori
TRThomas J. van Rijssen
Thomas J. van Rijssen
RTRoula Tsonaka
Roula Tsonaka
RDroselie diederen
roselie diederen
EDElon H.C. van Dijk
Elon H.C. van Dijk
Purpose: Assessing the 24‐month treatment outcome of half‐dose photodynamic therapy (PDT) or oral eplerenone in chronic central serous chorioretinopathy (cCSC). Methods: Multicentre randomized clinical trial included cCSC patients from the SPECTRA trial who were randomized to receive half‐dose PDT or oral eplerenone. Outcomes were evaluated at 24 months, including the primary outcome measure of complete resolution of subretinal fluid (SRF) on optical coherence tomography (OCT) and the secondary outcome measures best‐corrected visual acuity (BCVA), retinal and foveal sensitivity on microperimetry and the National Eye Institute Visual Functioning Questionnaire 25 (NEI‐VFQ25) score. Results: At baseline, 107 patients were included, of which 80 patients attended the final visit at 24 months: 40 had been randomized to primary treatment with half‐dose PDT and 40 to eplerenone. In the eplerenone group, as many as 36/40 (90%) needed crossover treatment at 3 months with half‐dose PDT due to persistent SRF, compared to 8/40 (20%) in the half‐dose PDT group. At the final visit, complete SRF resolution was observed in 32/40 (80%) who were primarily treated with half‐dose PDT and in 35/40 (88%) who received primary eplerenone treatment ( p = 0.609). There were no significant differences in terms of BCVA, foveal sensitivity, retinal sensitivity and NEI‐VFQ25 score. Conclusions: This study provides evidence for the long‐term efficacy of half‐dose PDT in resolving SRF and improving functional outcomes in cCSC. Even when patients initially received eplerenone treatment that did not result in complete SRF resolution, crossover treatment with half‐dose PDT led to similar (long‐term) group outcomes compared to half‐dose PDT as initial treatment.

16 March 2026 in American Journal of Ophthalmology
Verified
Journal Article
Open access
FTFemke M. van Den Tillaart
Femke M. van Den Tillaart
JCJennifer M. Chang-Wolf
Jennifer M. Chang-Wolf
HFHelena M.A. Feenstra
Helena M.A. Feenstra
TRThomas J. van Rijssen
Thomas J. van Rijssen
CHCarel B. Hoyng
Carel B. Hoyng
EDElon H.C. van Dijk
Elon H.C. van Dijk
To prospectively evaluate and compare long-term functional and structural outcomes between successful and unsuccessful first half-dose photodynamic therapy (PDT) in patients with chronic central serous chorioretinopathy (cCSC). Multicenter, prospective cohort study. Participants with cCSC enrolled in the PLACE and SPECTRA trials and treated with half-dose PDT in the participating Dutch medical centers, with visits at 5 to 10 years after inclusion. Participants were randomly assigned to half-dose PDT, oral eplerenone or high-density subthreshold micropulse laser and had protocol-defined retreatment and/or crossover treatment in case of persistent subretinal fluid (SRF). After 1 to 2 years of follow-up, patients were managed at clinicians' discretion and recalled for a 5 to 10-year visit. Best-corrected visual acuity (BCVA; measured in Early Treatment of Diabetic Retinopathy Study [ETDRS] letters), retinal sensitivity on microperimetry, presence of macular neovascularization, presence of SRF at long-term follow-up, recurrence of SRF, and retreatment during follow-up. Sixty percent (107/179) of eligible participants completed the long-term follow-up, performed at a median of 7.0 years. The first half-dose PDT was successful in 78 patients and unsuccessful in 29 patients. Due to a recurrence of SRF or persisting SRF, additional treatments were performed in 14.1% and 89.7% of patients in the successful and unsuccessful first PDT group during follow-up, respectively. BCVA at long-term follow-up was higher in the successful first PDT group (P < .001). Between baseline and long-term follow-up, BCVA increased significantly in the successful first PDT group (81.8 ± 7.8 vs 87.2 ± 8.7 ETDRS letters, P < .001), with the highest increase observed between baseline and the first control visit, followed by stabilization of BCVA thereafter. BCVA remained stable in the unsuccessful first PDT group (73.4 ± 12.1 vs 77.2 ± 16.2 ETDRS letters, P = .108). At long-term follow-up SRF was present in 16.7% and 44.8% of eyes in the successful and unsuccessful first PDT group, respectively (P = .005). cCSC patients with a successful first PDT show better long-term clinical outcomes than those with an unsuccessful first PDT. Notably, BCVA remained stable in both groups from the first follow-up after half-dose PDT onward, which is a reassuring finding even for patients without initial treatment success.

12 February 2026 in Acta Ophthalmologica
Verified
Journal Article
Open access
HFHelena M. A. Feenstra
Helena M. A. Feenstra
TCTahir Cakar
Tahir Cakar
JBJoost Brinks
Joost Brinks
CBCamiel Boon
Camiel Boon
EDElon H. C. van Dijk
Elon H. C. van Dijk
Purpose: To assess the risk of subretinal fluid (SRF) development in the fellow eye of chronic central serous chorioretinopathy (cCSC) patients with unilateral SRF at baseline. Methods: Medical records of 334 presumed cCSC patients were retrospectively reviewed. Multimodal imaging was evaluated, and the available optical coherence tomography (OCT) scans were screened for SRF development in the fellow eye during follow‐up. Results: Of 213 confirmed cCSC cases, 74 (35%) had bilateral SRF at baseline. Among 102 patients with unilateral SRF that met all inclusion criteria, 7/102 (7%) developed SRF in the fellow eye over a mean follow‐up of 20.4 months. Retinal pigment epithelial (RPE) alterations in the fellow eye were present at baseline in 7/7 (100%) who developed SRF, compared to 59/95 (62%) in those who did not ( p = 0.042). Subfoveal choroidal thickness (SFCT) was higher in the SRF‐developing group (482.3 vs. 365.9 μm; p = 0.306), although not significantly. Hyperautofluorescence on fundus autofluorescence (FAF) at baseline occurred in 6/7 (86%) of the SRF‐developing group versus 25/91 (28%) who did not ( p = 0.004). The ellipsoid zone was interrupted in 5/7 (71%) of SRF‐developing patients versus 28/95 (30%) who did not develop SRF ( p = 0.005). Conclusion: The risk of SRF development in the fellow eye of cCSC patients with unilateral SRF is relatively low over a follow‐up period of almost 2 years. No statistically significant risk factors were identified after correction for multiple testing; however, certain trends were observed.